Community-Acquired Bacterial Pneumonia – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of community-acquired bacterial pneumonia (CABP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the event rate of CABP for each country, as well as annualized event counts projected to the national population.
Clarivate Epidemiology’s CABP forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CABP over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts three CABP populations, as follows:
- Diagnosed CABP events
- Diagnosed CABP inpatient events
- Diagnosed CABP outpatient events
Note: Coverage may vary by country.
